Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 4/20 | 0.49 |
| ▸ | GABRD | O14764 | 4/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.49 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.49 |
| ▸ | GABRE | P78334 | 4/20 | 0.49 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.49 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.49 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.49 |
| ▸ | GABRQ | Q9UN88 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29590421 | 1.00 | GABRP (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL997135 | 0.81 | GABRP (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL243993 | 0.77 | GABRA1 (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL19857473 | 0.77 | KDM4E (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3509824 | 0.76 | GABRP (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL11427224 | 0.75 | GABRP (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL294836 | 0.73 | CYP1A2 (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL11427347 | 0.73 | KDM4E (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1974301 | 0.73 | GABRA1 (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL351540 | 0.73 | GABRP (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1352629-B1 | Use of a pyridine-dicarboxylic acid derivative or a salt thereof to stimulate or induce keratinic fiber growth and/or to prevent its loss | OREAL (FR) | 2011-06-22 | — | — | EP | claimed |
| US-7629368-B2 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2009-12-08 | — | — | US | disclosed |
| US-20090075952-A1 | NITRODERVIATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. | 2009-03-19 | — | — | US | disclosed |
| US-7465803-B2 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080194651-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. | 2008-08-14 | — | — | US | disclosed |
| EP-1339665-B1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX SA (FR) | 2007-12-19 | — | — | EP | disclosed |
| US-20040023933-A1 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2004-02-05 | — | — | US | disclosed |
| EP-1339665-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | Nicox S.A. (FR) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002030866-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. (FR) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075952-A1 | NITRODERVIATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NR3C1, NR0B1, NOX1 | GABRP 2149/4885GABRD 1669/4885GABRA1 2313/4885 |
| US-20080194651-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NR3C1, NR2E1, CYP2E1 | GABRP 1973/4885GABRD 1395/4885GABRA1 1530/4885 |
| US-20040023933-A1 | Nitroderivatives as drugs for diseases having an inflammatory basis | TPMT, NOX1, CBR1 | GABRP 2753/4885GABRD 2259/4885GABRA1 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.